Biomaterials for enhancing anti-cancer immunity

被引：101
|
作者：
Koshy, Sandeep T. [1 ,2 ,3 ]
Mooney, David J. [1 ,2 ]
机构：
[1] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA
[2] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA
[3] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
来源：
CURRENT OPINION IN BIOTECHNOLOGY | 2016年 / 40卷
关键词：
LYMPH-NODE; IN-VIVO; DELIVERY-SYSTEMS; DENDRITIC CELLS; CANCER; VACCINES; NANOPARTICLES; IMMUNOTHERAPY; SCAFFOLDS; MICROENVIRONMENT;
D O I：
10.1016/j.copbio.2016.02.001
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Cancer immunotherapy is becoming a standard approach to treat many cancers. However, shortcomings of current methods limit therapeutic benefit in many patients. Rationally designed biomaterial strategies to deliver immune modulatory drugs can potentially show improved safety profiles, while providing multifunctional and spatiotemporally controlled signals to immune cells to improve their anticancer activity. This brief review describes biomaterialsbased strategies that enhance immune cell function at various tissue sites to improve anti-cancer immunity. Continued collaboration between bioengineers, immunologists, industry, and clinicians is required for biomaterial-based immunotherapy strategies to continue moving to the clinic.
引用
收藏
页码：1 / 8
页数：8
相关论文
共 50 条
  • [41] Cancer Associated Fibroblasts-An Impediment to Effective Anti-Cancer T Cell Immunity
    Koppensteiner, Lilian
    Mathieson, Layla
    O'Connor, Richard A.
    Akram, Ahsan R.
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Adjuvant cationic nanoliposomes induce anti-cancer immunity in a murine model of breast cancer
    Meraz, Ismail M.
    Savage, David J.
    Gu, Jianhua
    Rhudy, Jessica
    Serda, Rita E.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [43] Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Iero, Manuela
    Filipazzi, Paola
    Castelli, Chiara
    Belli, Filiberto
    Valdagni, Riccardo
    Parmiani, Giorgio
    Patuzzo, Roberto
    Santinami, Mario
    Rivoltini, Licia
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (07) : 1159 - 1167
  • [44] Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Manuela Iero
    Paola Filipazzi
    Chiara Castelli
    Filiberto Belli
    Riccardo Valdagni
    Giorgio Parmiani
    Roberto Patuzzo
    Mario Santinami
    Licia Rivoltini
    [J]. Cancer Immunology, Immunotherapy, 2009, 58 : 1159 - 1167
  • [45] Mesoporous Silicon Particles for the Presentation of Tumor Antigens and Adjuvant for Anti-Cancer Immunity
    Meraz, I. M.
    Melendez, B.
    Gu, J.
    Serda, R. E.
    [J]. CANCER RESEARCH, 2011, 71
  • [46] Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
    Dwivedi, Mitesh
    Tiwari, Sanjay
    Kemp, E. Helen
    Begum, Rasheedunnisa
    [J]. HELIYON, 2022, 8 (08)
  • [47] BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
    Samanta, Debangshu
    Huang, Tina Yi-Ting
    Shah, Rima
    Yang, Yongkang
    Pan, Fan
    Semenza, Gregg L.
    [J]. CELL REPORTS, 2020, 32 (08):
  • [48] Innate-like T cells: A promising asset in anti-cancer immunity
    Molgora, Martina
    Colonna, Marco
    [J]. CANCER CELL, 2022, 40 (07) : 714 - 716
  • [49] Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity
    Lee, Bo-Ram
    Lee, Hyo-Jung
    Huh, June
    Yoon, Chul Joo
    Oh, Se Jin
    Song, Kwon-Ho
    Jeong, Sojin
    Kim, Jungwon
    Lee, Kyung-Mi
    Shin, Beom Soo
    Jeong, Ji Hoon
    Kim, Tae Woo
    Lee, Jeewon
    [J]. ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [50] Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity
    Wang, Yufeng
    Song, Mei
    Liu, Ming
    Zhang, Guoan
    Zhang, Xian
    Li, Ming O.
    Ma, Xiaojing
    Zhang, J. Jillian
    Huang, Xin-Yun
    [J]. CELL REPORTS, 2021, 35 (01):
12345